XTL Biopharmaceuticals Ltd.
Clinical-stage biopharmaceutical company developing drugs for autoimmune diseases.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Manufacturing
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-04 00:17 |
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 111.2 KB | ||
| 2025-02-04 00:17 |
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 36.3 KB | ||
| 2024-12-31 08:29 |
6K-financial results for the nine months ended September 30, 2024
|
English | 150.7 KB | ||
| 2024-12-31 08:29 |
6K-financial results for the nine months ended September 30, 2024
|
English | 36.2 KB | ||
| 2024-12-31 08:27 |
6K- financial results for the six months ended June 30, 2024
|
English | 152.3 KB | ||
| 2024-12-31 08:27 |
6K- financial results for the six months ended June 30, 2024
|
English | 36.2 KB | ||
| 2024-11-20 09:41 |
Form 6-K- As previously disclosed, on November 11, 2024- entered into a settlem…
|
English | 113.2 KB | ||
| 2024-11-20 09:41 |
Form 6-K- As previously disclosed, on November 11, 2024- entered into a settlem…
|
English | 36.3 KB | ||
| 2024-11-12 17:52 |
Resolution of the controversy arisen between the Company and its subsidiary in…
|
English | 115.3 KB | ||
| 2024-11-12 17:52 |
Resolution of the controversy arisen between the Company and its subsidiary in…
|
English | 36.3 KB | ||
| 2024-10-15 18:26 |
Update in connection to the immediate report dated 14.8.24
|
English | 113.4 KB | ||
| 2024-10-15 18:26 |
Update in connection to the immediate report dated 14.8.24
|
English | 36.3 KB | ||
| 2024-08-14 18:56 |
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1…
|
English | 178.0 KB | ||
| 2024-08-14 18:56 |
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1…
|
English | 36.3 KB | ||
| 2024-07-23 01:14 |
Results of the Annual and Extraordinary Meeting held on July 22, 2024
|
English | 133.7 KB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XTL Biopharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
